Genome-wide association studies: Powerful tools for improving drug safety and efficacy

Pharmacogenomics

Volumn 10, Issue 2, 2009, Pages 157-159

  Gurwitz, David ^a   McLeod, Howard L ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; DAUNORUBICIN; LAPATINIB; METHYLPHENIDATE; RECOMBINANT BETA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR; TAMOXIFEN; DRUG;

ATTENTION DEFICIT DISORDER; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEREDITY; HOSPITAL ADMISSION; HUMAN; MULTIPLE SCLEROSIS; NICOTINE REPLACEMENT THERAPY; PATENT; PHARMACOGENOMICS; PHENOTYPE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; DRUG THERAPY; GENOMICS; HUMAN GENOME; METHODOLOGY; STANDARD;

DRUG THERAPY; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 65549115939     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.2.157     Document Type: Editorial

References (20)

1. Kruglyak L: The road to genome-wide association studies. Nat. Rev. Genet. 9(4), 314-318 (2008).
2. McCarthy MI, Abecasis GR, Cardon LR et al.: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008).
3. Khoury MJ, Wacholder S: Invited commentary: from genome-wide association studies to gene-environment-wide interaction studies - challenges and opportunities. Am. J. Epidemiol. 169(2), 227-230 (2009).
4. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL: National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15), 1858-1866 (2006).
5. Gurwitz D, McLeod HL: Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics 8(4), 311-314 (2007).
6. Pirmohamed M, James S, Meakin S et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456), 15-19 (2004).
7. Need AC, Motulsky AG, Goldstein DB: Priorities and standards in pharmacogenetic research. Nat. Genet. 37(7), 671-681 (2005).
8. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y: When good drugs go bad. Nature 446(7139), 975-977 (2007).
9. Sato Y, Laird NM, Nagashima K et al.: A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J. (2008) (Epub ahead of print).
10. Sarasquete ME, García-Sanz R, Marín L et al.: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112(7), 2709-2712 (2008).
11. Inada T, Koga. M, Ishiguro H et al.: Pathway-based association analysis of genome-wide screening data suggest that genes associated with the γ-aminoburyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet. Genomics 18(4), 317-323 (2008).
12. Gurwitz D, Weizman A: Personalized psychiatry: a realistic goal. Pharmacogenomics 5(2), 213-217 (2004).
13. de Leon J: Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34(1), 159-172 (2009).
14. Byun E, Caillier SJ, Montalban X et al.: Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis. Arch. Neurol. 65(3), 337-344 (2008).
15. Liu C, Batliwalla F, Li W et al.: Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9-10), 575-581 (2008).
16. Uhl GR, Liu QR, Drgon T et al.: Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch. Gen. Psychiatry 65(6), 683-693 (2008).
17. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV: Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(8), 1412-1418 (2008).
18. Huang RS, Duan S, Kistner EO et al.: Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 68(9), 3161-3168 (2008).
19. Masri S, Phung S, Wang X et al.: Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res. 68(12), 4910-4918 (2008).
20. Greshock J, Cheng J, Rusnak D et al.: Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Mol. Cancer Ther. 7(4), 935-943 (2008).